The burgeoning landscape of therapeutic interventions for obesity disorders has witnessed considerable attention focused on GLP-3 analogues and, more recently, the dual GIP and GLP-3 co-agonist retatrutide. While both https://junaidkahb102431.wiki-jp.com/2003886/glp_3_retatrutide_a_comparative_analysis